MRNA · News · 20261112N
Operating Expense Trends
Moderna, Inc. · 2026-11-12 · Importance 64 · Surprise 42 · In source text
Moderna set a 2027 cash cost target of about $4 billion at its 2026 Analyst Day. Quantisnow reported that this target exceeded the midpoint of the company’s previous guidance. The report linked increased expected spending particularly to oncology investment and said the company did not provide a 2027 revenue forecast. Other reporting said Moderna plans to increase oncology investment through 2030.
Key facts
- Moderna's stock fell 6.97% after its 2026 Analyst Day, where it provided a 2027 cash cost target of about $4 billion. source
- Moderna's approximately $4 billion 2027 cash cost target exceeded the midpoint of its previous guidance. source
- Moderna planned increased investment in oncology through 2030. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | committed | — | Moderna's approximately $4 billion 2027 cash cost target exceeded the midpoint of its previous guidance. |
| cash | negative | committed | — | Moderna's approximately $4 billion 2027 cash cost target exceeded the midpoint of its previous guidance. |